| Year |
Citation |
Score |
| 2024 |
Fecteau RE, Koontz BF, Hoffman KE, Halabi S, Howard LE, Anand M, George DJ, Zhang T, Berry WR, Lee WR, Harrison MR, Corn PG, Armstrong AJ. Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 38388778 DOI: 10.1038/s41391-024-00811-5 |
0.411 |
|
| 2023 |
Murphy K, Kehoe B, Denieffe S, Hacking D, Fairman CM, Harrison M. A comparison of aerobic- and resistance-emphasised exercise on cardiometabolic health and quality of life in men receiving androgen deprivation therapy for prostate cancer: Protocol for a feasibility trial. Contemporary Clinical Trials. 107388. PMID 37972755 DOI: 10.1016/j.cct.2023.107388 |
0.391 |
|
| 2023 |
Murphy K, Denieffe S, Kehoe B, Hacking D, Fairman CM, Harrison M. Designing effective exercise intervention trials for prostate cancer cohorts: a qualitative study on experiences and views of exercise oncology researchers. Bmc Sports Science, Medicine & Rehabilitation. 15: 145. PMID 37904240 DOI: 10.1186/s13102-023-00756-7 |
0.321 |
|
| 2022 |
Hanson ED, Alzer M, Carver J, Stopforth CK, Lucas AR, Whang YE, Milowsky MI, Bartlett DB, Harrison MR, Bitting RL, Deal AM, Stoner L, Hackney AC, Battaglini CL. Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 35306542 DOI: 10.1038/s41391-022-00523-8 |
0.404 |
|
| 2022 |
Brown LC, Halabi S, Somarelli JA, Humeniuk M, Wu Y, Oyekunle T, Howard L, Huang J, Anand M, Davies C, Patel P, Staats J, Weinhold KJ, Harrison MR, Zhang T, et al. A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 35292724 DOI: 10.1038/s41391-022-00524-7 |
0.45 |
|
| 2022 |
Zhang T, Kephart J, Bronson E, Anand M, Daly C, Spasojevic I, Bakthavatsalam S, Franz K, Berg H, Karachaliou GS, James OG, Howard L, Halabi S, Harrison MR, Armstrong AJ, et al. Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer. The Prostate. PMID 35286730 DOI: 10.1002/pros.24329 |
0.341 |
|
| 2022 |
Harrison MR, Davis PG, Khouri MG, Bartlett DB, Gupta RT, Armstrong AJ, McNamara MA, Zhang T, Anand M, Onyenwoke K, Edwardson S, Craig D, Michalski M, Wu Y, Oyekunle T, et al. A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND). Prostate Cancer and Prostatic Diseases. PMID 35273377 DOI: 10.1038/s41391-022-00519-4 |
0.655 |
|
| 2021 |
Autio KA, Antonarakis ES, Mayer TM, Shevrin DH, Stein MN, Vaishampayan UN, Morris MJ, Slovin SF, Heath EI, Tagawa ST, Rathkopf DE, Milowsky MI, Harrison MR, Beer TM, Balar AV, et al. Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. European Urology Open Science. 34: 70-78. PMID 34934969 DOI: 10.1016/j.euros.2021.09.015 |
0.337 |
|
| 2021 |
George DJ, Halabi S, Heath EI, Sartor AO, Sonpavde GP, Das D, Bitting RL, Berry W, Healy P, Anand M, Winters C, Riggan C, Kephart J, Wilder R, Shobe K, ... ... Harrison MR, et al. A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. Cancer. PMID 33951180 DOI: 10.1002/cncr.33589 |
0.695 |
|
| 2021 |
Hanson ED, Stopforth CK, Alzer M, Carver J, Lucas AR, Whang YE, Milowsky MI, Bartlett DB, Harrison MR, Hayes A, Bitting RL, Deal AM, Hackney AC, Battaglini CL. Body composition, physical function and quality of life in healthy men and across different stages of prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 33495569 DOI: 10.1038/s41391-020-00317-w |
0.344 |
|
| 2021 |
Zhang T, Koontz BF, Tagawa ST, Nagar H, Bitting RL, Frizzell B, Nordquist LT, Rasmussen J, Wilder R, Anand M, Winters C, Riggan C, Fernandez E, Healy P, Oyekunle T, ... ... Harrison MR, et al. Interim analysis of STARTAR: A phase II salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP). Journal of Clinical Oncology. 39: 90-90. DOI: 10.1200/JCO.2021.39.6_SUPPL.90 |
0.705 |
|
| 2021 |
Brown LC, Halabi S, Humeniuk MS, Wu Y, Oyekunle T, Huang J, Anand M, Davies C, Zhang T, Harrison MR, George DJ, Armstrong AJ. Efficacy of the PD-L1 inhibitor avelumab in neuroendocrine or aggressive variant prostate cancer: Results from a phase II, single-arm study. Journal of Clinical Oncology. 39: 89-89. DOI: 10.1200/JCO.2021.39.6_SUPPL.89 |
0.393 |
|
| 2020 |
Koontz BF, Hoffman KE, Halabi S, Healy P, Anand M, George DJ, Harrison MR, Zhang T, Berry WR, Corn PG, Lee WR, Armstrong AJ. Combination of Radiotherapy and Short-Term Androgen Blockade with Abiraterone Acetate plus Prednisone for Men with High and Intermediate Risk Localized Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 33259932 DOI: 10.1016/j.ijrobp.2020.11.059 |
0.377 |
|
| 2020 |
Armstrong AJ, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand M, Berry WR, Zhang T, Harrison MR, Lu C, Chen Y, Galletti G, Schonhoft JD, et al. Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. Jco Precision Oncology. 4. PMID 33154984 DOI: 10.1200/PO.20.00200 |
0.449 |
|
| 2020 |
Powers E, Karachaliou GS, Kao C, Harrison MR, Hoimes CJ, George DJ, Armstrong AJ, Zhang T. Novel therapies are changing treatment paradigms in metastatic prostate cancer. Journal of Hematology & Oncology. 13: 144. PMID 33115529 DOI: 10.1186/s13045-020-00978-z |
0.423 |
|
| 2020 |
Bitting RL, Healy P, George DJ, Anand M, Kim S, Mayer T, Winters C, Riggan C, Rasmussen J, Wilder R, Stein M, Frizzell B, Harrison MR, Zhang T, Lee WR, et al. Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial. European Urology Oncology. PMID 32063492 DOI: 10.1016/J.Euo.2020.01.005 |
0.444 |
|
| 2019 |
Narayan V, Harrison M, Cheng H, Kenfield S, Aggarwal R, Kwon D, McKay R, Hauger R, Hart N, Conzen S, Borno H, Jim H, Dicker A, Dorff T, Moslehi J, et al. Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. Urologic Oncology. PMID 31734020 DOI: 10.1016/J.Urolonc.2019.10.006 |
0.4 |
|
| 2019 |
George DJ, Halabi S, Healy P, Barak I, Winters C, Anand M, Wilder R, Klein M, Martinez E, Nixon AB, Harrison MR, Szmulewitz R, Armstrong AJ. Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. The Prostate. PMID 31497882 DOI: 10.1002/Pros.23899 |
0.384 |
|
| 2019 |
Tucker MD, Zhu J, Marin D, Gupta RT, Gupta S, Berry WR, Ramalingam S, Zhang T, Harrison M, Wu Y, Healy P, Lisi S, George DJ, Armstrong AJ. Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer. Cancer Medicine. PMID 31270961 DOI: 10.1002/Cam4.2375 |
0.445 |
|
| 2019 |
Holl EK, McNamara MA, Healy P, Anand M, Concepcion RS, Breland CD, Dumbudze I, Tutrone R, Shore N, Armstrong AJ, Harrison M, Wallace JA, Wu Y, George DJ. Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients. Prostate Cancer and Prostatic Diseases. PMID 30980027 DOI: 10.1038/S41391-019-0144-3 |
0.688 |
|
| 2019 |
Labriola MK, Batich KA, Zhu J, McNamara MA, Harrison MR, Armstrong AJ, George DJ, Zhang T. Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma. Clinical Genitourinary Cancer. PMID 30858035 DOI: 10.1016/J.Clgc.2019.01.017 |
0.592 |
|
| 2019 |
Hanson ED, Carver JL, Lucas A, Bass M, Alzer M, Whang Y, Harrison M, Milowsky MI, Bitting RL, Battaglini CL. High Adherence To Home-Based Exercise Improves Muscle Strength And Cardiorespiratory Fitness With Advanced Prostate Cancer: 74 Board #5 May 29 9:30 AM - 11:30 AM Medicine and Science in Sports and Exercise. 51: 6-7. DOI: 10.1249/01.Mss.0000560506.05468.17 |
0.326 |
|
| 2019 |
Armstrong AJ, Bitting RL, Healy P, George DJ, Kim S, Mayer TM, Winters C, Riggan C, Rasmussen J, Wilder R, Anand M, Stein MN, Frizzell B, Harrison MR, Zhang T, et al. Phase II trial enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in men with high-risk PSA recurrent prostate cancer (PC): The STREAM trial. Journal of Clinical Oncology. 37: 29-29. DOI: 10.1200/Jco.2019.37.7_Suppl.29 |
0.454 |
|
| 2019 |
Harrison MR, Khouri M, Armstrong AJ, Zhang T, McNamara MA, Anand M, Bratt E, Hood H, Coyne B, Wu Y, Healy P, George DJ. PEAX: Men with metastatic castrate-resistant prostate cancer (mCRPC) treated with either sipuleucel-T (SIP-T), enzalutamide (ENZA) or abiraterone acetate (ABI) undergoing cardiopulmonary exercise testing (CPET). Journal of Clinical Oncology. 37: 281-281. DOI: 10.1200/Jco.2019.37.7_Suppl.281 |
0.67 |
|
| 2019 |
Tucker MD, Zhu J, Berry WR, Ramalingam S, Zhang T, Harrison MR, Wu Y, Healy P, George DJ, Armstrong AJ. Pembrolizumab in men with heavily treated metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 37: 172-172. DOI: 10.1200/Jco.2019.37.7_Suppl.172 |
0.44 |
|
| 2019 |
Zhang T, Koontz BF, Tagawa ST, Nagar H, Bitting RL, Frizzell B, Rasmussen J, Wilder R, Anand M, Winters C, Riggan C, Lee A, Healy P, Wu Y, McNamara MA, ... Harrison MR, et al. A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (STARTAR). Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps5097 |
0.689 |
|
| 2019 |
Zhu J, Tucker MD, Kao C, Labriola M, Cheris S, Datto MB, Wu Y, Healy P, Gupta S, Kirtane K, Gupta RT, Marin D, Zhang T, McNamara MA, Harrison MR, et al. Immune checkpoint inhibitor response in tumors with LRP1B variants. Journal of Clinical Oncology. 37: e14291-e14291. DOI: 10.1200/Jco.2019.37.15_Suppl.E14291 |
0.662 |
|
| 2019 |
Autio KA, Antonarakis ES, Baser R, Stein MN, Shevrin DH, Vaishampayan UN, Mayer TM, Morris MJ, Slovin SF, Heath EI, Tagawa ST, Rathkopf DE, Milowsky MI, Harrison MR, Beer TM, et al. Evaluation of the patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) with abiraterone acetate plus prednisone (AAP), degarelix (D), or the combination in men with biochemically recurrent prostate cancer (BCRPC). Journal of Clinical Oncology. 37: 5080-5080. DOI: 10.1200/Jco.2019.37.15_Suppl.5080 |
0.36 |
|
| 2019 |
Mara A, Zhu J, Wu Y, Callis T, Yang S, Esplin ED, Nussbaum RL, Zhang T, McNamara MA, Harrison MR, George DJ, Cooney KA, Armstrong AJ. Prevalence of pathogenic germline variants in DNA repair by race, age, and ethnicity in men with prostate cancer. Journal of Clinical Oncology. 37: 5062-5062. DOI: 10.1200/Jco.2019.37.15_Suppl.5062 |
0.667 |
|
| 2018 |
Harrison MR, Davis PG, Khouri MG, Gupta RT, Armstrong AJ, McNamara MA, Zhang T, Anand M, Onyenwoke K, Hood H, Edwardson S, Craig D, Wu Y, Healy P, Coyne B, et al. EXTEND: Safety and efficacy of exercise training in men receiving enzalutamide (ENZ) in combination with conventional androgen deprivation therapy (ADT) for hormone naïve prostate cancer (HSPC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii623-viii624. PMID 32137677 DOI: 10.1093/annonc/mdy300.064 |
0.682 |
|
| 2018 |
Hanlon A, Fleming S, Hamilton AS, Dinan MA, Melloni C, Harrison MR, Khouri M, Wu X, Wilson JF, Lipscomb J, Cress RD, Anderson RT, Kimmick GG. Androgen deprivation therapy (ADT) and cardiovascular mortality (CVD) in men with early-stage prostate cancer (PC) receiving curative radiation therapy (RT). Journal of Clinical Oncology. 36: 127-127. DOI: 10.1200/Jco.2018.36.7_Suppl.127 |
0.312 |
|
| 2018 |
Koontz BF, Hoffman KE, Healy P, George DJ, Harrison MR, Zhang T, Lee WR, Berry WR, Pugh TJ, Corn PG, Bratt L, Shobe K, Thornburg B, Allen DM, Brummer K, et al. Phase II trial of 6 months ADT/abiraterone acetate plus prednisone (AAP) and definitive radiotherapy (AbiRT) for men with intermediate to high risk localized prostate cancer. Journal of Clinical Oncology. 36: 11-11. DOI: 10.1200/Jco.2018.36.6_Suppl.11 |
0.449 |
|
| 2018 |
George DJ, Heath EI, Sartor AO, Sonpavde G, Berry WR, Healy P, Winters C, Riggan C, Anand M, Kephart J, Milowsky MI, Fleming MT, Balaji KC, Zhang T, Bitting RL, ... Harrison MR, et al. Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP). Journal of Clinical Oncology. 36: LBA5009-LBA5009. DOI: 10.1200/Jco.2018.36.18_Suppl.Lba5009 |
0.652 |
|
| 2018 |
Autio KA, Antonarakis ES, Mayer TM, Vaishampayan UN, Shevrin DH, Harrison MR, Tagawa ST, Milowsky MI, Graff JN, Beer TM, Balar AV, Stein M, Heath EI, Armstrong AJ, Paller CJ, et al. Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP+D), and degarelix (D) alone for patients (pts) with biochemically-recurrent prostate cancer (PC) following radical prostatectomy (RP). Journal of Clinical Oncology. 36: 5016-5016. DOI: 10.1200/Jco.2018.36.15_Suppl.5016 |
0.394 |
|
| 2018 |
Koontz B, Hoffman K, Healy P, George D, Harrison M, Zhang T, Lee W, Berry W, Pugh T, Bratt L, Hobbs B, Halabi S, Corn P, Armstrong A, Shobe K, et al. Two Year Outcomes of Short-Term Potent Androgen Blockade and Definitive Radiation for Intermediate to High Risk Localized Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 102: S100. DOI: 10.1016/J.Ijrobp.2018.06.256 |
0.341 |
|
| 2017 |
Humeniuk MS, Gupta RT, Healy P, McNamara M, Ramalingam S, Harrison M, George D, Zhang T, Wu Y, Armstrong AJ. Platinum sensitivity in metastatic prostate cancer: does histology matter? Prostate Cancer and Prostatic Diseases. PMID 29230006 DOI: 10.1038/S41391-017-0017-6 |
0.7 |
|
| 2017 |
Ramalingam S, Humeniuk MS, Hu R, Rasmussen J, Healy P, Wu Y, Harrison MR, Armstrong AJ, George DJ, Zhang T. Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer. Urologic Oncology. PMID 28126272 DOI: 10.1016/J.Urolonc.2016.12.016 |
0.432 |
|
| 2017 |
Humeniuk MS, Gupta RT, McNamara MA, Ramalingam S, Harrison MR, George DJ, Wu Y, Healy P, Armstrong AJ. Association of neuroendocrine phenotype with platinum chemotherapy outcomes in men with metastatic prostate cancer. Journal of Clinical Oncology. 35: e16532-e16532. DOI: 10.1200/Jco.2017.35.15_Suppl.E16532 |
0.709 |
|
| 2016 |
Armstrong AJ, Humeniuk MS, Healy P, Szmulewitz R, Winters C, Kephart J, Harrison MR, Martinez E, Mundy K, Halabi S, George D. Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial. The Prostate. PMID 27862097 DOI: 10.1002/Pros.23277 |
0.412 |
|
| 2016 |
Ramalingam S, Eisenberg A, Foo WC, Freedman J, Armstrong AJ, Moss LG, Harrison MR. Treatment-related neuroendocrine prostate cancer resulting in Cushing's syndrome. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 27766686 DOI: 10.1111/Iju.13225 |
0.359 |
|
| 2016 |
Glass OK, Ramalingam S, Harrison MR. Resistance exercise training in patients with genitourinary cancers to mitigate treatment-related skeletal muscle loss. Clinical Advances in Hematology & Oncology : H&O. 14: 436-46. PMID 27379813 |
0.323 |
|
| 2016 |
Harrison MR, Ramalingam S. Novel Androgen Receptor Signaling Inhibitors for Nonmetastatic Castration-Resistant Prostate Cancer: The Light at the End of the Tunnel-or an Oncoming Train? Oncology (Williston Park, N.Y.). 30. PMID 27085333 |
0.32 |
|
| 2016 |
George DJ, Halabi S, Healy P, Gemberling S, Winters C, Mundy K, Harrison MR, Szmulewitz RZ, Armstrong AJ. Phase Ib trial of docetaxel, prednisone, and pazopanib, in men with metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 34: 275-275. DOI: 10.1200/Jco.2016.34.2_Suppl.275 |
0.444 |
|
| 2016 |
Ramalingam S, Humeniuk MS, Hu R, Rasmussen J, Healy P, Wu Y, Harrison MR, Armstrong AJ, George DJ, Zhang T. PSA response in black and white patients treated with abiraterone acetate (AA) for metastatic castrate-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 34: 5033-5033. DOI: 10.1200/Jco.2016.34.15_Suppl.5033 |
0.437 |
|
| 2015 |
Ramalingam S, Pollak KI, Zullig LL, Harrison MR. What Should We Tell Patients About Physical Activity After a Prostate Cancer Diagnosis? Oncology (Williston Park, N.Y.). 29: 680-5, 687-8, 694. PMID 26384805 |
0.395 |
|
| 2015 |
Palvai S, Harrison M, Shibu Thomas S, Hayden K, Green J, Anderson O, Romero L, Lodge R, Burns P, Ahmed I. Timing of High-Dose Rate Brachytherapy With External Beam Radiotherapy in Intermediate and High-Risk Localized Prostate CAncer (THEPCA) Patients and Its Effects on Toxicity and Quality of Life: Protocol of a Randomized Feasibility Trial. Jmir Research Protocols. 4: e49. PMID 25926023 DOI: 10.2196/Resprot.4462 |
0.445 |
|
| 2015 |
Stover JT, Moore RA, Davis K, Harrison MR, Armstrong AJ. Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 18: 161-6. PMID 25777155 DOI: 10.1038/Pcan.2015.7 |
0.39 |
|
| 2015 |
Zhang T, Dhawan MS, Healy P, George DJ, Harrison MR, Oldan J, Chin B, Armstrong AJ. Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 13: 392-9. PMID 25708161 DOI: 10.1016/J.Clgc.2015.01.004 |
0.407 |
|
| 2015 |
Harrison MR, Armstrong AJ. Burden of disease matters when it comes to systemic therapy for prostate cancer. European Urology. 67: 448-50. PMID 24612662 DOI: 10.1016/J.Eururo.2014.02.032 |
0.424 |
|
| 2014 |
Bhavsar NA, Harrison MR, Howie LJ, Armstrong AJ, Davis K, Chen Q, Pupa MR, Abernethy A, George DJ, Hirsch BR. 1072PEXPERIENCE OF PATIENTS TREATED WITH SIPULEUCEL-T IN AN ACADEMIC SETTING. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv369-iv370. PMID 28171524 DOI: 10.1093/Annonc/Mdu342.25 |
0.381 |
|
| 2013 |
George DJ, Armstrong AJ, Harrison MR. Highlights in advanced prostate cancer from the 2013 American Urological Association Annual Meeting and the 2013 American Society of Clinical Oncology Annual Meeting: commentary. Clinical Advances in Hematology & Oncology : H&O. 11: 16-22. PMID 25856023 |
0.315 |
|
| 2013 |
Harrison MR, Wong TZ, Armstrong AJ, George DJ. Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Management and Research. 5: 1-14. PMID 23326203 DOI: 10.2147/Cmar.S25537 |
0.311 |
|
| 2013 |
Antonarakis ES, Heath EI, Posadas EM, Yu EY, Harrison MR, Bruce JY, Cho SY, Wilding GE, Fetterly GJ, Hangauer DG, Kwan MF, Dyster LM, Carducci MA. A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology. 71: 883-92. PMID 23314737 DOI: 10.1007/S00280-013-2079-Z |
0.403 |
|
| 2012 |
Antonarakis ES, Heath EI, Posadas EM, Harrison MR, Bruce JY, Yu EY, Cho SY, Wilding GE, Fetterly GJ, Hangauer DG, Kwan MR, Dyster LM, Carducci MA. A phase II study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer (CRPC): A PCCTC trial. Journal of Clinical Oncology. 30: 4654-4654. DOI: 10.1200/Jco.2012.30.15_Suppl.4654 |
0.383 |
|
| 2011 |
Harrison MR, Hahn NM, Pili R, Oh WK, Hammers H, Sweeney C, Kim K, Perlman S, Arnott J, Sidor C, Wilding G, Liu G. A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Investigational New Drugs. 29: 1465-74. PMID 20499131 DOI: 10.1007/S10637-010-9455-X |
0.416 |
|
| 2008 |
Harrison MR, Hahn N, Pili R, Oh WK, Kim K, Wilding G, Sweeney CJ, Sidor C, Arnott J, Liu G. Phase II study of 2-methoxyestradiol (2ME2) NanoCrystal Dispersion (NCD) in patients with taxane-refractory, metastatic hormone-refractory prostate cancer (HRPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5173. PMID 27948238 DOI: 10.1200/Jco.2008.26.15_Suppl.5173 |
0.39 |
|
| Show low-probability matches. |